Mesoblast shares plunge after FDA questions treatment
MELBOURNE: Shares in Stem-cell focused biotech Mesoblast dived more than 30 per cent ...
To read the full story...SUBSCRIBE NOWExisting Subscribers Login Below:
Log In
